Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread

Oncotarget

Volumn 7, Issue 26, 2016, Pages 39640-39653

  Bachmayr Heyda, Anna ^a   Auer, Katharina ^a   Sukhbaatar, Nyamdelger ^a   Aust, Stefanie ^a   Deycmar, Simon ^a   Reiner, Agnes T ^a   Polterauer, Stephan ^a   Dekan, Sabine ^b   Pils, Dietmar ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Competing endogenous RNA network; Ovarian cancer; Peritoneal tumor spread; Prognostic signature; Small RNA sequencing

Indexed keywords

CIRCULAR RNA; LONG UNTRANSLATED RNA; MICRORNA; PIWI INTERACTING RNA DERIVATIVE; RIBOSOME RNA; RNA DERIVATIVE; SMALL RNA DERIVATIVE; UNCLASSIFIED DRUG; RNA; RNA, CIRCULAR; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; ASCITES; CANCER CELL; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; EPITHELIUM CELL; EPITHELIUM TUMOR; FEMALE; GENE CONTROL; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC CODE; HIGH GRADE SEROUS OVARIAN CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; OVARY CANCER; PERITONEUM METASTASIS; PERITONEUM TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA SEQUENCE; UPREGULATION; VALIDATION STUDY; CYSTADENOCARCINOMA; GENETICS; METASTASIS; MIDDLE AGED; OVARY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SEQUENCE ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; OVARY; PERITONEAL NEOPLASMS; PROGNOSIS; RNA; RNA, LONG NONCODING; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, RNA;

EID: 84982893494     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9243     Document Type: Article

References (39)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000; 19:3-10.
3. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol. 2011; 223:102-115.
4. Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS letters. 2011; 585: 2087-2099.
5. Dai Q, Li J, Zhou K, Liang T. Competing endogenous RNA: A novel posttranscriptional regulatory dimension associated with the progression of cancer. Oncology letters. 2015; 10:2683-2690.
6. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. The international journal of biochemistry & cell biology. 2010; 42:1273-1281.
7. Cho WC. MicroRNAs in cancer - from research to therapy. Biochimica et biophysica acta. 2010; 1805:209-217.
8. Naqvi AR, Islam MN, Choudhury NR, Haq QM. The fascinating world of RNA interference. International journal of biological sciences. 2009; 5:97-117.
9. Cheng J, Guo JM, Xiao BX, Miao Y, Jiang Z, Zhou H, Li QN. piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. Clinica chimica acta. 2011; 412: 1621-1625.
10. Moyano M, Stefani G. piRNA involvement in genome stability and human cancer. Journal of hematology & oncology. 2015; 8:38.
11. Auer K, Bachmayr-Heyda A, Aust S, Sukhbaatar N, Reiner AT, Grimm C, Horvat R, Zeillinger R, Pils D. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget. 2015; 6:17261-17275. doi:10.18632/oncotarget.3746.
12. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic acids research. 2014; 42:D68-73.
13. Friedlander MR, Lizano E, Houben AJ, Bezdan D, BanezCoronel M, Kudla G, Mateu-Huertas E, Kagerbauer B, Gonzalez J, Chen KC, LeProust EM, Marti E, Estivill X. Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome biology. 2014; 15:R57.
14. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci USA. 2015; 112:E1106-1115.
15. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013; 495:333-338.
16. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495:384-388.
17. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeillinger R, Pils D. Correlation of circular RNA abundance with proliferation-exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. Scientific reports. 2015; 5:8057.
18. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
19. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nature reviews Clinical oncology. 2010; 7:508-519.
20. Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, et al. Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium. Cancer Sci. 2012; 103:1334-41.
21. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14:5198-5208.
22. Creighton CJ, Benham AL, Zhu H, Khan MF, Reid JG, Nagaraja AK, Fountain MD, Dziadek O, Han D, Ma L, Kim J, Hawkins SM, Anderson ML, et al. Discovery of novel microRNAs in female reproductive tract using next generation sequencing. PloS one. 2010; 5:e9637.
23. Koppers-Lalic D, Hackenberg M, Bijnsdorp IV, van Eijndhoven MA, Sadek P, Sie D, Zini N, Middeldorp JM, Ylstra B, de Menezes RX, Wurdinger T, Meijer GA, Pegtel DM. Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. Cell reports. 2014; 8:1649-1658.
24. Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Laboratory investigation. 1995; 72:506-512.
25. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007; 13:78-83.
26. Zecchini S, Bombardelli L, Decio A, Bianchi M, Mazzarol G, Sanguineti F, Aletti G, Maddaluno L, Berezin V, Bock E, Casadio C, Viale G, Colombo N, et al. The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO molecular medicine. 2011; 3:480-494.
27. Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Trope C, Nesland JM, Thiery JP. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. Hum Pathol. 2015; 46:1-8.
28. Ledda F, Paratcha G, Sandoval-Guzman T, Ibanez CF. GDNF and GFRalpha1 promote formation of neuronal synapses by ligand-induced cell adhesion. Nature neuroscience. 2007; 10:293-300.
29. Sato T, Arai E, Kohno T, Tsuta K, Watanabe S, Soejima K, Betsuyaku T, Kanai Y. DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PloS one. 2013; 8:e59444.
30. Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci USA. 2014; 111:E672-681.
31. Das M, Prasad SB, Yadav SS, Govardhan HB, Pandey LK, Singh S, Pradhan S, Narayan G. Over expression of minichromosome maintenance genes is clinically correlated to cervical carcinogenesis. PloS one. 2013; 8:e69607.
32. Ishimi Y, Irie D. G364R mutation of MCM4 detected in human skin cancer cells affects DNA helicase activity of MCM4/6/7 complex. Journal of biochemistry. 2015; 157:561-569.
33. Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, et al. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. European journal of cancer. 2014; 50:99-110.
34. Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, et al. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients-a study of the OVCAD consortium. BMC Cancer. 2013; 13:422.
35. Stocks MB, Moxon S, Mapleson D, Woolfenden HC, Mohorianu I, Folkes L, Schwach F, Dalmay T, Moulton V. The UEA sRNA workbench: a suite of tools for analysing and visualizing next generation sequencing microRNA and small RNA datasets. Bioinformatics. 2012; 28:2059-2061.
36. An J, Lai J, Lehman ML, Nelson CC. miRDeep*: an integrated application tool for miRNA identification from RNA sequencing data. Nucleic acids research. 2013; 41:727-737.
37. Rosenkranz D, Zischler H. proTRAC-a software for probabilistic piRNA cluster detection, visualization and analysis. BMC bioinformatics. 2012; 13:5.
38. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PloS one. 2009; 4:e6098.
39. Cox DR. Regression Models and Life-Tables. J Roy Stat Soc B. 1972; 34:187-&.